Literature DB >> 12183115

Monoamine oxidase: radiotracer development and human studies.

Joanna S Fowler1, Jean Logan, Nora D Volkow, Gene-Jack Wang, Robert R MacGregor, Yu-Shin Ding.   

Abstract

Monoamine oxidase (MAO) is an integral protein of outer mitochondrial membranes and occurs in neuronal and nonneuronal cells in the brain and in peripheral organs. It oxidizes amines from both endogenous and exogenous sources, thereby influencing the concentration of neurotransmitter amines as well as many xenobiotics. It occurs in two subtypes, MAO A and MAO B, which are different gene products and have different substrate and inhibitor specificities. Both MAO A and B can be imaged and quantified in the living human brain using positron emission tomography (PET) and radiotracers labeled with carbon-11. PET studies have been carried out to measure the effects of age, MAO inhibitor drugs, tobacco smoke exposure, and other factors on MAO activity in the human brain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183115     DOI: 10.1016/s1046-2023(02)00083-x

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  17 in total

Review 1.  Translational neuroimaging: positron emission tomography studies of monoamine oxidase.

Authors:  Joanna S Fowler; Jean Logan; Nora D Volkow; Gene-Jack Wang
Journal:  Mol Imaging Biol       Date:  2005 Nov-Dec       Impact factor: 3.488

Review 2.  Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases.

Authors:  Dale E Edmondson; Claudia Binda; Jin Wang; Anup K Upadhyay; Andrea Mattevi
Journal:  Biochemistry       Date:  2009-05-26       Impact factor: 3.162

3.  PET radiopharmaceuticals for probing enzymes in the brain.

Authors:  Jason P Holland; Paul Cumming; Neil Vasdev
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-04-09

Review 4.  Type A monoamine oxidase and serotonin are coordinately involved in depressive disorders: from neurotransmitter imbalance to impaired neurogenesis.

Authors:  Makoto Naoi; Wakako Maruyama; Masayo Shamoto-Nagai
Journal:  J Neural Transm (Vienna)       Date:  2017-03-14       Impact factor: 3.575

5.  MicroRNA-132 dysregulation in Toxoplasma gondii infection has implications for dopamine signaling pathway.

Authors:  J Xiao; Y Li; E Prandovszky; S S Karuppagounder; C C Talbot; V L Dawson; T M Dawson; R H Yolken
Journal:  Neuroscience       Date:  2014-03-18       Impact factor: 3.590

Review 6.  Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.

Authors:  Jacobus P Petzer; Neal Castagnoli; Michael A Schwarzschild; Jiang-Fan Chen; Cornelis J Van der Schyf
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

7.  Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases A and B by 2-aryl-2-fluoro-cyclopropylamines.

Authors:  Svenja Hruschka; Thomas C Rosen; Shinichi Yoshida; Kenneth L Kirk; Roland Fröhlich; Birgit Wibbeling; Günter Haufe
Journal:  Bioorg Med Chem       Date:  2008-06-28       Impact factor: 3.641

8.  Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography.

Authors:  A Pal; A Glekas; M Doubrovin; J Balatoni; Mohammed Namavari; T Beresten; D Maxwell; S Soghomonyan; A Shavrin; L Ageyeva; R Finn; S M Larson; W Bornmann; J G Gelovani
Journal:  Mol Imaging Biol       Date:  2006 Sep-Oct       Impact factor: 3.484

9.  Synthesis and Initial Characterization of a Reversible, Selective 18F-Labeled Radiotracer for Human Butyrylcholinesterase.

Authors:  Christian Gentzsch; Xinyu Chen; Philipp Spatz; Urban Košak; Damijan Knez; Naoko Nose; Stanislav Gobec; Takahiro Higuchi; Michael Decker
Journal:  Mol Imaging Biol       Date:  2021-03-03       Impact factor: 3.488

10.  Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.

Authors:  Ryan R Gordon; Mengchu Wu; Chung-Ying Huang; William P Harris; Hong Gee Sim; Jared M Lucas; Ilsa Coleman; Celestia S Higano; Roman Gulati; Lawrence D True; Robert Vessella; Paul H Lange; Mark Garzotto; Tomasz M Beer; Peter S Nelson
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.